BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37679307)

  • 1. Aptamer/Peptide-Functionalized Nanoprobe for Detecting Multiple miRNAs in Circulating Malignant Cells to Study Tumor Heterogeneity.
    Han D; Ren XH; He XY; Chen XS; Pang X; Cheng SX
    ACS Biomater Sci Eng; 2023 Oct; 9(10):5832-5842. PubMed ID: 37679307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Multiple Targeting Nanoprobe for Identifying Cancer Metastatic Sites Based on Detection of Various mRNAs in Circulating Tumor Cells.
    Han D; Ren XH; Liao XR; He XY; Guo T; Chen XS; Pang X; Cheng SX
    Nano Lett; 2023 May; 23(9):3678-3686. PubMed ID: 37052638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct detection of intracellular miRNA in living circulating tumor cells by tumor targeting nanoprobe in peripheral blood.
    Xu C; He XY; Ren XH; Cheng SX
    Biosens Bioelectron; 2021 Oct; 190():113401. PubMed ID: 34119837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of mRNAs of Ribosomal Protein L15 and E-Cadherin in Living Circulating Tumor Cells at Single Cell Resolution To Study Tumor Heterogeneity.
    Xu C; He XY; Ren XH; Han D; Cheng SX
    Anal Chem; 2022 Aug; 94(30):10610-10616. PubMed ID: 35856393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
    Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
    Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enrichment of circulating melanoma cells (CMCs) using negative selection from patients with metastatic melanoma.
    Joshi P; Jacobs B; Derakhshan A; Moore LR; Elson P; Triozzi PL; Borden E; Zborowski M
    Oncotarget; 2014 May; 5(9):2450-61. PubMed ID: 24811334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients.
    Alunni-Fabbroni M; Majunke L; Trapp EK; Tzschaschel M; Mahner S; Fasching PA; Fehm T; Schneeweiss A; Beck T; Lorenz R; Friedl TWP; Janni W; Rack B;
    BMC Cancer; 2018 Feb; 18(1):141. PubMed ID: 29409452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Situ Detection of Nanotoxicity in Living Cells Based on Multiple miRNAs Probed by a Peptide Functionalized Nanoprobe.
    Han D; Xu C; Ren XH; Peng Y; Xu B; Song JL; Chen J; Cheng SX
    Anal Chem; 2022 Feb; 94(5):2399-2407. PubMed ID: 35099175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay.
    Magbanua MJ; Pugia M; Lee JS; Jabon M; Wang V; Gubens M; Marfurt K; Pence J; Sidhu H; Uzgiris A; Rugo HS; Park JW
    PLoS One; 2015; 10(10):e0141166. PubMed ID: 26496203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
    Cheng HH; Plets M; Li H; Higano CS; Tangen CM; Agarwal N; Vogelzang NJ; Hussain M; Thompson IM; Tewari M; Yu EY
    Prostate; 2018 Feb; 78(2):121-127. PubMed ID: 29105802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular MicroRNA Imaging and Specific Discrimination of Prostate Cancer Circulating Tumor Cells Using Multifunctional Gold Nanoprobe-Based Thermophoretic Assay.
    Luo S; Meng X; Xu LP; Zhang X
    Anal Chem; 2024 Feb; 96(5):2217-2226. PubMed ID: 38262909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of miR-10b expression in circulating tumor cells.
    Gasch C; Plummer PN; Jovanovic L; McInnes LM; Wescott D; Saunders CM; Schneeweiss A; Wallwiener M; Nelson C; Spring KJ; Riethdorf S; Thompson EW; Pantel K; Mellick AS
    Sci Rep; 2015 Nov; 5():15980. PubMed ID: 26522916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer.
    McAnena P; Tanriverdi K; Curran C; Gilligan K; Freedman JE; Brown JAL; Kerin MJ
    BMC Cancer; 2019 May; 19(1):436. PubMed ID: 31077182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal detection of subcategorized CD44v6
    Wang Y; Zhang L; Tan J; Zhang Z; Liu Y; Hu X; Lu B; Gao Y; Tong L; Liu Z; Zhang H; Lin PP; Li B; Gires O; Zhang T
    Cancer Lett; 2023 Sep; 571():216337. PubMed ID: 37553013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1
    Zhang L; Zhang X; Liu Y; Zhang T; Wang Z; Gu M; Li Y; Wang DD; Li W; Lin PP
    Cancer Lett; 2020 Jan; 469():355-366. PubMed ID: 31678168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of miR-21 with Circulating Tumor Cells Markers Improve Diagnostic Specificity of Metastatic Breast Cancer.
    Yang X; Wang X; Shen H; Deng R; Xue K
    Cell Biochem Biophys; 2015 Sep; 73(1):87-91. PubMed ID: 25669446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct Comparison of Metastasis-Related miRNAs Expression Levels in Circulating Tumor Cells, Corresponding Plasma, and Primary Tumors of Breast Cancer Patients.
    Markou A; Zavridou M; Sourvinou I; Yousef G; Kounelis S; Malamos N; Georgoulias V; Lianidou E
    Clin Chem; 2016 Jul; 62(7):1002-11. PubMed ID: 27197674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy.
    Rodríguez-Martínez A; de Miguel-Pérez D; Ortega FG; García-Puche JL; Robles-Fernández I; Exposito J; Martorell-Marugan J; Carmona-Sáez P; Garrido-Navas MDC; Rolfo C; Ilyine H; Lorente JA; Legueren M; Serrano MJ
    Breast Cancer Res; 2019 Feb; 21(1):21. PubMed ID: 30728048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of two methods for the detection of circulating tumour cells in patients with oral cavity cancer.
    Curtin J; Wong G; Wang W; Thomson P; Lam AK; Choi SW
    J Oral Pathol Med; 2022 Mar; 51(3):249-255. PubMed ID: 34586677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The presence of clustered circulating tumor cells (CTCs) and circulating cytokines define an aggressive phenotype in metastatic colorectal cancer.
    Divella R; Daniele A; Abbate I; Bellizzi A; Savino E; Simone G; Giannone G; Giuliani F; Fazio V; Gadaleta-Caldarola G; Gadaleta CD; Lolli I; Sabbà C; Mazzocca A
    Cancer Causes Control; 2014 Nov; 25(11):1531-41. PubMed ID: 25135616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.